497 research outputs found
Geochemical modeling of magmatic gas scrubbing
The EQ3/6 software package, version 7.2 was successfully used to model scrubbing of magmatic gas by pure
water at 0.1 MPa, in the liquid and liquid-plus-gas regions. Some post-calculations were necessary to account
for gas separation effects. In these post-calculations, redox potential was considered to be fixed by precipitation
of crystalline a-sulfur, a ubiquitous and precocious process. As geochemical modeling is constrained by conservation
of enthalpy upon water-gas mixing, the enthalpies of the gas species of interest were reviewed, adopting
as reference state the liquid phase at the triple point. Our results confirm that significant emissions of highly
acidic gas species (SO2(g), HCl(g), and HF(g)) are prevented by scrubbing, until dry conditions are established, at
least locally. Nevertheless important outgassing of HCl(g) can take place from acid, HCl-rich brines. Moreover,
these findings support the rule of thumb which is generally used to distinguish SO2-, HCl-, and HF-bearing magmatic
gases from SO2-, HCl-, and HF-free hydrothermal gases
A novel combination of fipronil and permethrin (Frontline Tri-Act®/Frontect®) reduces risk of transmission of Babesia canis by Dermacentor reticulatus and of Ehrlichia canis by Rhipicephalus sanguineus ticks to dogs
BACKGROUND : The ability of Frontline Tri-Act®/Frontect®, a topical ectoparasiticide containing fipronil and permethrin
for dogs, to prevent the transmission of Babesia canis as well as Ehrlichia canis was evaluated by infesting dogs with
infected vector ticks.
METHODS : For the Babesia canis study, 16 dogs were randomly allocated to two groups. Eight dogs were treated on
day 0 with a topical spot-on formulation containing 6.76 % w/v fipronil plus 50.48 % w/v permethrin and eight dogs
served as the untreated control group. Dermacentor reticulatus ticks, with a B. canis infection rate ranging between
2 and 10 %, were placed onto dogs on days 7, 14, 21 and 28. In situ tick counts were performed on Days 9, 16 and
23. Ticks were counted and removed on Day 30. Infection of the dogs with B. canis was monitored by rectal temperature
readings, clinical examinations and blood smears as well as PCR and IFA (indirect fluorescent antibody assay).
For the Ehrlichia canis study, another 16 dogs were allocated to two groups. Eight dogs were treated with the fipronil and
permethrin combination on days 0 and 28 and eight dogs served as untreated controls. Rhipicephalus sanguineus ticks,
carrying an infection rate of 13 % for E. canis, were released in the sleeping kennels of the dogs on days 7, 14, 21, 28, 35,
42, 49 and 56. Ticks were counted in situ on the dogs on a weekly basis. All ticks were removed and counted on the final
assessment day 58. Infection of the dogs with E. canis was monitored by rectal temperature, clinical examinations, and
testing of blood samples by PCR, IFA and platelet counts.
RESULTS : B. canis was transmitted by D. reticulatus ticks to all eight untreated control dogs and to one treated dog, which
was confirmed by blood smears, PCR and IFA. E.canis was transmitted by R. sanguineus ticks to all eight untreated control
dogs. Two of the dogs in the treated group were found positive based on PCR and/or IFA.
CONCLUSIONS : Frontline Tri-Act®/Frontect® significantly lowered the risk for dogs to acquire a B. canis infection by 87.5 %
over a challenge period of 28 days. The risk for dogs to acquire E. canis was reduced by 75 % over a period of 56 days.Merial S.A.S., a Sanofi company, France.http://www.parasitesandvectors.comam201
Allopatric speciation in ticks: genetic and reproductive divergence between geographic strains of Rhipicephalus (Boophilus) microplus
12 pages, 5 figures.-- PMID: 19243585 [PubMed].-- PMCID: PMC2656471.-- Supporting information (Microsatellite genotypes of individual tick crosses, XLS file) available at: http://www.biomedcentral.com/content/supplementary/1471-2148-9-46-s1.xls.-- et al.[Background]: The cattle tick, Rhipicephalus (Boophilus) microplus, economically impact cattle industry in tropical and subtropical regions of the world. The morphological and genetic differences among R. microplus strains have been documented in the literature, suggesting that biogeographical and ecological separation may have resulted in boophilid ticks from America/Africa and those from Australia being different species. To test the hypothesis of the presence of different boophilid species, herein we performed a series of experiments to characterize the reproductive performance of crosses between R. microplus from Australia, Africa and America and the genetic diversity of strains from Australia, Asia, Africa and America.[Results]: The results showed that the crosses between Australian and Argentinean or Mozambican strains of boophilid ticks are infertile while crosses between Argentinean and Mozambican strains are fertile. These results showed that tick strains from Africa (Mozambique) and America (Argentina) are the same species, while ticks from Australia may actually represent a separate species. The genetic analysis of mitochondrial 12S and 16S rDNA and microsatellite loci were not conclusive when taken separately, but provided evidence that Australian tick strains were genetically different from Asian, African and American strains.[Conclusion]: The results reported herein support the hypothesis that at least two different species share the name R. microplus. These species could be redefined as R. microplus (Canestrini, 1887) (for American and African strains) and probably the old R. australis Fuller, 1899 (for Australian strains), which needs to be redescribed. However, experiments with a larger number of tick strains from different geographic locations are needed to corroborate these results.This work was supported by ICTTD-3, financed by the International Cooperation Program of the European Union, coordination action project No. 510561, the ConsejerĂa de EducaciĂłn y Ciencia, JCCM, Spain (project PAI06-0046-5285) (to JF), the Conselho Nacional de Desenvolvimento CientĂfico e TecnolĂłgico – CNPq (to MBL), the Consejo Nacional de Investigaciones CientĂcas y TĂ©cnicas de Argentina (PIP 2058) and INTA Rafaela (TCP 426100) (to AJM, AAG and CT). V. Naranjo was funded by Junta de Comunidades de Castilla–La Mancha (JCCM), Spain.Peer reviewe
Maternal diabetes causes developmental delay and death in early-somite mouse embryos
Maternal diabetes causes congenital malformations and delays embryonic growth in the offspring. We investigated effects of maternal diabetes on mouse embryos during gastrulation and early organogenesis (ED7.5-11.5). Female mice were made diabetic with streptozotocin, treated with controlled-release insulin implants, and mated. Maternal blood glucose concentrations increased up to embryonic day (ED) 8.5. Maternal hyperglycemia induced severe growth retardation (approx.1 day) in 53% of the embryos on ED8.5, death in most of these embryos on ED9.5, and the termination of pregnancy on ED10.5 in litters with >20% dead embryos. Due to this selection, developmental delays and reduction in litter size were no longer observed thereafter in diabetic pregnancies. Male and female embryos were equally sensitive. High-throughput mRNA sequencing and pathway analysis of differentially expressed genes showed that retarded embryos failed to mount the adaptive suppression of gene expression that characterized non-retarded embryos (cell proliferation, cytoskeletal remodeling, oxidative phosphorylation). We conclude that failure of perigastrulation embryos of diabetic mothers to grow and survive is associated with their failure to shut down pathways that are strongly down-regulated in otherwise similar non-retarded embryos. Embryos that survive the early and generalized adverse effect of maternal diabetes, therefore, appear the subset in which malformations become manifest
Effect of Hyperglycemia on Gene Expression during Early Organogenesis in Mice
BACKGROUND: Cardiovascular and neural malformations are common sequels of diabetic pregnancies, but the underlying molecular mechanisms remain unknown. We hypothesized that maternal hyperglycemia would affect the embryos most shortly after the glucose-sensitive time window at embryonic day (ED) 7.5 in mice. METHODS: Mice were made diabetic with streptozotocin, treated with slow-release insulin implants and mated. Pregnancy aggravated hyperglycemia. Gene expression profiles were determined in ED8.5 and ED9.5 embryos from diabetic and control mice using Serial Analysis of Gene Expression and deep sequencing. RESULTS: Maternal hyperglycemia induced differential regulation of 1,024 and 2,148 unique functional genes on ED8.5 and ED9.5, respectively, mostly in downward direction. Pathway analysis showed that ED8.5 embryos suffered mainly from impaired cell proliferation, and ED9.5 embryos from impaired cytoskeletal remodeling and oxidative phosphorylation (all P ≤ E-5). A query of the Mouse Genome Database showed that 20-25% of the differentially expressed genes were caused by cardiovascular and/or neural malformations, if deficient. Despite high glucose levels in embryos with maternal hyperglycemia and a ~150-fold higher rate of ATP production from glycolysis than from oxidative phosphorylation on ED9.5, ATP production from both glycolysis and oxidative phosphorylation was reduced to ~70% of controls, implying a shortage of energy production in hyperglycemic embryos. CONCLUSION: Maternal hyperglycemia suppressed cell proliferation during gastrulation and cytoskeletal remodeling during early organogenesis. 20-25% of the genes that were differentially regulated by hyperglycemia were associated with relevant congenital malformations. Unexpectedly, maternal hyperglycemia also endangered the energy supply of the embryo by suppressing its glycolytic capacity
Comparative efficacy of oral administrated afoxolaner (NexGard™) and fluralaner (Bravecto™) with topically applied permethrin/imidacloprid (Advantix®) against transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs
BACKGROUND : The ability of the topical spot-on Advantix® (50 % permethrin/10 % imidacloprid) to prevent
transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs has previously been reported. The
recent market introduction of chewable tablets containing the novel compounds, afoxolaner (NexGard™) and
fluralaner (Bravecto™) enabled us to conduct a comparative efficacy study with respect to the ability of these three
products to block transmission of E. canis by ticks to dogs. The speed of kill, immediate drop-off rate and
anti-attachment efficacy of the respective products were also studied.
METHODS : The study was a blinded parallel group design, wherein 32 dogs were randomised into four different
groups of eight dogs. Group 1 served as negative placebo control, group 2 and 3 were treated on Days 0, 28 and
56 with NexGard™ and Advantix®, respectively. Group 4 was dosed once on Day 0 with Bravecto™. For tick efficacy
assessments 50 non-infected ticks were placed onto the dogs on Days 30, 35, 42, 49, 56, 63, 70, 77 and 84 and on
animal tick counts were performed at 3 h, 6 h and 12 h after infestation. To evaluate the ability to block transmission of
E. canis, each dog was challenged by releasing 80 adult E. canis-infected R. sanguineus ticks into their sleeping kennels
on Days 31, 38, 45 and 52. The animals were monitored for clinical signs of monocytic ehrlichiosis (pyrexia and
thrombocytopenia) and were tested for E. canis DNA by PCR and for specific antibodies using IFA. A dog was
considered infected with E. canis if both PCR and IFA yielded positive test results up to Day 84.
RESULTS : Mean arithmetic tick counts on dogs treated with the Advantix® spot-on were significantly (P < 0.0005) lower
throughout the study as compared with the negative controls and was, with respect to the speed of kill and resulting
onset of acaricidal efficacy, superior over NexGard™ and Bravecto™ at all time points in the 12 h period observed (3 h,
6 h and 12 h). None of the dogs treated with the Advantix® spot-on became infected with E. canis, whereas six out of
eight untreated control dogs acquired the infection. Furthermore, E. canis infection was diagnosed in four out of eight
dogs treated with NexGard™ and in two out of eight dogs treated with Bravecto™.
CONCLUSIONS : The speed of kill of the two recently registered systemic compounds against R. sanguineus was not
sufficiently fast to prevent transmission of E. canis and resulted in only low partial blocking and protection capacity
while Advantix® effectively blocked transmission of E. canis to dogs in the challenge period and thus provided
adequate protection for dogs against monocytic ehrlichiosis.Bayer Animal Health GmbH, Monheim,
Germanyhttp://www.parasitesandvectors.comam2016Veterinary Tropical Disease
Lymphoma-associated mutations in autoreactive memory B cells of patients with Sjögren's syndrome
We recently demonstrated that normal memory B lymphocytes carry a substantial number of de novo mutations in the genome. Here, we performed exome-wide somatic mutation analyses of bona fide autoreactive rheumatoid factor (RF)-expressing memory B cells retrieved from patients with SjÓ§gren's syndrome (SS). The amount and repertoire of the de novo exome mutations of RF B cells were found to be essentially different from those detected in healthy donor memory B cells. In contrast to the mutation spectra of normal B cells, which appeared random and non-selected, the mutations of the RF B cells were greater in number and enriched for mutations in genes also found mutated in B-cell non-Hodgkin lymphomas. During the study, one of the SS patients developed a diffuse large B-cell lymphoma (DLBCL) out of an RF clone that was identified 2 years earlier in an inflamed salivary gland biopsy. The successive oncogenic events in the RF precursor clone and the DLBCL were assessed. In conclusion, our findings of enhanced and selected genomic damage in growth-regulating genes in RF memory B cells of SS patients together with the documented transformation of an RF-precursor clone into DLBCL provide unique novel insight into the earliest stages of B-cell derailment and lymphomagenesis.</p
- …